Bevacizumab Injection
Formulation (FDF) · Injection · 100mg（4ml）/bottle
Formulation (FDF)Confidentiality：Public
- INN / Generic Name
- Bevacizumab Injection
- Dosage Form
- Injection
- Strength
- 100mg（4ml）/bottle
- Therapy Area
- Oncology
- Indication
- Metastatic colorectal cancer; Advanced-stage non-small cell lung cancer; Metastatic non-small cell lung cancer; Recurrent non-small cell lung cancer; Recurrent glioblastoma; Epithelial ovarian cancer; Fallopian tube cancer; Primary peritoneal cancer; Cervical cancer; Hepatocellular carcinoma
- Current Status
- Official FDF licensing catalog (UB763)
- GMP Certification
- CN - NMPA
- CEP
- No
- DMF Type
- —
- Stability Data
- —
- BE Required
- Not required / waivable
- Registration Pathway
- Registered (market rights transferable / DCP·NP per market)
- MOQ
- On request
- Lead Time
- On request
- Price Range
- On request
HS Code
3004.903 customs bills on file
Registrable Markets
China
Process / Sequence / Exact Price
- Process Summary
- —
- Exact Price